EUVIMEDEUVIMED entdecken
Open Access

The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response

Lulzim Shkreta, Johanne Toutant, Aurélie Delannoy, David Durantel, Anna Salvetti, Sophie Ehresmann, Martin Sauvageau, Julien A Delbrouck, Alice Gravel-Trudeau, Christian Comeau, Caroline Huard, Jasmin Coulombe-Huntington und 4 weitere

Oncotarget · 16.05.2024 · 15 (1) · 313-325

DOI: 10.18632/oncotarget.28585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncotarget, online erschienen am 16.05.2024. Verfasst von Lulzim Shkreta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Cell Proliferation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionProtein-Tyrosine KinasesProtein Kinase InhibitorsCell ProliferationHumansCell Line, TumorAntineoplastic AgentsProtein Serine-Threonine KinasesThiazolesAntiviral AgentsHCT116 CellsDEAD-box RNA HelicasesGene Expression Profiling

Stichwörter der Autor:innen

CLK kinases inhibitorsEMTantiviral immune responsemetastasismicrotubules

Substanzen

Protein-Tyrosine KinasesProtein Kinase InhibitorsAntineoplastic AgentsProtein Serine-Threonine KinasesThiazolesAntiviral AgentsDEAD-box RNA HelicasesClk dual-specificity kinases

Autor:innen und Institutionen

  • Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • International Center for Infectiology Research (CIRI), INSERM U1111, CNRS UMR5308, Université de Lyon (UCBL1), Lyon, France.
  • Institut de recherches cliniques de Montréal, Montréal, QC, Canada.
  • Department of Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke and Institut de Pharmacologie, Sherbrooke, QC, Canada.
  • Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

Förderung

  • NIH HHS

Zitieren

APA

Shkreta, L., Toutant, J., Delannoy, A., Durantel, D., Salvetti, A., Ehresmann, S., Sauvageau, M., Delbrouck, J. A., Gravel-Trudeau, A., Comeau, C., Huard, C., Coulombe-Huntington, J., Tyers, M., Grierson, D., Boudreault, P. L., & Chabot, B. (2024). The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response. Oncotarget, 15(1), 313-325. https://doi.org/10.18632/oncotarget.28585

Vancouver

Shkreta L, Toutant J, Delannoy A, Durantel D, Salvetti A, Ehresmann S, et al. The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response. Oncotarget. 2024;15(1):313-325. doi:10.18632/oncotarget.28585

BibTeX
@article{Shkreta2024,
  author = {Shkreta, Lulzim and Toutant, Johanne and Delannoy, Aurélie and Durantel, David and Salvetti, Anna and Ehresmann, Sophie and Sauvageau, Martin and Delbrouck, Julien A and Gravel-Trudeau, Alice and Comeau, Christian and Huard, Caroline and Coulombe-Huntington, Jasmin and Tyers, Mike and Grierson, David and Boudreault, Pierre-Luc and Chabot, Benoit},
  title = {The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response},
  journal = {Oncotarget},
  year = {2024},
  volume = {15},
  number = {1},
  pages = {313--325},
  doi = {10.18632/oncotarget.28585}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche